December 16, 2017, Gmax Biopharm LLC., a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today announced that it has initiated a phase 1 clinical trial of GMA301 in healthy volunteers in Australia.

The first-in-human, placebo-controlled, double-blinded, dose-escalation phase 1 study is designed to investigate the safety, tolerability and pharmacokinetics of GMA301 in healthy volunteers.

GMA301 is the first ETa antibody therapeutic candidate in the world, for treatment of pulmonary arterial hypertension (PAH), a lethal rare disease. It has been granted with “Orphan Drug Designation” by FDA, and was selected as the national “Mega-Innovative Program” in China.